Zobrazeno 1 - 10
of 372
pro vyhledávání: '"Kazuko Matsumoto"'
Autor:
Daisuke Tamura, Tokuzo Arao, Tomoyuki Nagai, Hiroyasu Kaneda, Keiichi Aomatsu, Yoshihiko Fujita, Kazuko Matsumoto, Marco A. DeVelasco, Hiroaki Kato, Hidetoshi Hayashi, Shuhei Yoshida, Hideharu Kimura, Yoshimasa Maniwa, Wataru Nishio, Yasuhiro Sakai, Chiho Ohbayashi, Yoshikazu Kotani, Yoshihiro Nishimura, Kazuto Nishio
Publikováno v:
Cancer Medicine, Vol 2, Iss 2, Pp 144-154 (2013)
Abstract Transcription factor Slug/SNAI2 (snail homolog 2) plays a key role in the induction of the epithelial mesenchymal transition in cancer cells; however, whether the overexpression of Slug mediates the malignant phenotype and alters drug sensit
Externí odkaz:
https://doaj.org/article/7a2bcae70ceb4d6aa10388d1dcd58260
Autor:
Kaoru Tanaka, Tokuzo Arao, Daisuke Tamura, Keiichi Aomatsu, Kazuyuki Furuta, Kazuko Matsumoto, Hiroyasu Kaneda, Kanae Kudo, Yoshihiko Fujita, Hideharu Kimura, Kazuyoshi Yanagihara, Yasuhide Yamada, Isamu Okamoto, Kazuhiko Nakagawa, Kazuto Nishio
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e27922 (2012)
SRPX2 (Sushi repeat-containing protein, X-linked 2) has recently emerged as a multifunctional protein that is involved in seizure disorders, angiogenesis and cellular adhesion. Here, we analyzed this protein biochemically. SRPX2 protein was secreted
Externí odkaz:
https://doaj.org/article/3fa9c2af71e94becb7d16390f15e752c
Autor:
Kazuko, MATSUMOTO
Publikováno v:
東京理科大学教養教育研究院紀要 創刊号. 1:112-125
Autor:
Kazuko Matsumoto
Publikováno v:
Pragmatics. Quarterly Publication of the International Pragmatics Association (IPrA). :163-181
Publikováno v:
Modern Rheumatology. 33:381-391
Objectives To assess the real-world safety and effectiveness of canakinumab in patients in Japan with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) or mevalonate kinase deficiency/hyperimmunoglobulinaemia D with periodic fever
Autor:
Kazuto Nishio, Masatoshi Kudo, Nagahiro Saijo, Kazuko Matsumoto, Yoshihiko Fujita, Hideharu Kimura, Keiichi Aomatsu, Daisuke Tamura, Hiroyasu Kaneda, Kanae Kudo, Kazuko Sakai, Kazuyuki Furuta, Tokuzo Arao, Tomoyuki Nagai
Supplementary Figures 1-5 from Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72ac10c120b3fe794e966f736c11be4e
https://doi.org/10.1158/1535-7163.22483866.v1
https://doi.org/10.1158/1535-7163.22483866.v1
Autor:
Kazuto Nishio, Masatoshi Kudo, Nagahiro Saijo, Yoshihiko Fujita, Marco A. De Velasco, Keiichi Aomatsu, Daisuke Tamura, Kazuko Matsumoto, Hiroyasu Kaneda, Kazuko Sakai, Kazuyuki Furuta, Tomoyuki Nagai, Kaoru Tanaka, Tokuzo Arao, Kanae Kudo
Purpose: BIBF 1120 is a potent, orally available triple angiokinase inhibitor that inhibits VEGF receptors (VEGFR) 1, 2, and 3, fibroblast growth factor receptors, and platelet-derived growth factor receptors. This study examined the antitumor effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::290335ebbb8795f2dc515fa7a390aef8
https://doi.org/10.1158/1078-0432.c.6519036
https://doi.org/10.1158/1078-0432.c.6519036
Autor:
Kazuto Nishio, Masatoshi Kudo, Nagahiro Saijo, Kazuko Matsumoto, Yoshihiko Fujita, Hideharu Kimura, Keiichi Aomatsu, Daisuke Tamura, Hiroyasu Kaneda, Kanae Kudo, Kazuko Sakai, Kazuyuki Furuta, Tokuzo Arao, Tomoyuki Nagai
Supplementary Figure Legends from Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e804f6c9095821d1f1710d28769d498
https://doi.org/10.1158/1535-7163.22483869.v1
https://doi.org/10.1158/1535-7163.22483869.v1
Autor:
Kazuto Nishio, Masatoshi Kudo, Nagahiro Saijo, Yoshihiko Fujita, Marco A. De Velasco, Keiichi Aomatsu, Daisuke Tamura, Kazuko Matsumoto, Hiroyasu Kaneda, Kazuko Sakai, Kazuyuki Furuta, Tomoyuki Nagai, Kaoru Tanaka, Tokuzo Arao, Kanae Kudo
Supplementary Figures S1-S3; Supplementary Tables S1-S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8657c33cceff5c7b0f45864c4b0c6fa
https://doi.org/10.1158/1078-0432.22442247.v1
https://doi.org/10.1158/1078-0432.22442247.v1
Autor:
Kazuto Nishio, Masatoshi Kudo, Nagahiro Saijo, Kazuko Matsumoto, Yoshihiko Fujita, Hideharu Kimura, Keiichi Aomatsu, Daisuke Tamura, Hiroyasu Kaneda, Kanae Kudo, Kazuko Sakai, Kazuyuki Furuta, Tokuzo Arao, Tomoyuki Nagai
The epithelial mesenchymal transition (EMT) has emerged as a pivotal event in the development of the invasive and metastatic potentials of cancer progression. Sorafenib, a VEGFR inhibitor with activity against RAF kinase, is active against hepatocell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c0b0dbeeb12e6494284443439bd9304
https://doi.org/10.1158/1535-7163.c.6531258
https://doi.org/10.1158/1535-7163.c.6531258